ABUS
Arbutus Biopharma Corp
NASDAQ: ABUS · HEALTHCARE · BIOTECHNOLOGY
$4.13
-0.48% today
Updated 2026-04-29
Market cap
$813.36M
P/E ratio
—
P/S ratio
57.75x
EPS (TTM)
$-0.17
Dividend yield
—
52W range
$3 – $5
Volume
2.5M
Arbutus Biopharma Corp (ABUS) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-237.90%
Operating margin
-727.00%
ROE
-38.50%
ROA
-14.90%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $13.60M | $18.08M | 54.53% | -12.36% | 132.90% |
| 2007 | $15.92M | $-2.58M | 100.00% | 16.57% | -16.22% |
| 2008 | $9.64M | $-11.72M | -37.43% | -113.58% | -121.56% |
| 2009 | $13.78M | $-9.33M | -23.12% | -65.79% | -67.68% |
| 2010 | $21.35M | $-12.41M | -3.65% | -58.61% | -58.14% |
| 2011 | $16.30M | $-9.73M | -19.54% | -63.32% | -59.69% |
| 2012 | $14.18M | $29.95M | -27.82% | -91.62% | 211.19% |
| 2013 | $15.46M | $-14.06M | -38.76% | -78.59% | -90.95% |
| 2014 | $15.00M | $-38.80M | -158.00% | -220.00% | -258.67% |
| 2015 | $24.87M | $-61.12M | -107.07% | -411.38% | -245.73% |
| 2016 | $1.50M | $-384.10M | -3,986.67% | -32,773.33% | -25,606.67% |
| 2017 | $10.70M | $-84.40M | -485.98% | -1,036.45% | -788.79% |
| 2018 | $5.90M | $-57.10M | -881.36% | -1,522.03% | -967.80% |
| 2019 | $6.01M | $-153.72M | -858.26% | -2,393.96% | -2,557.36% |
| 2020 | $6.91M | $-63.74M | -586.74% | -836.07% | -921.97% |
| 2021 | $10.99M | $-76.25M | 100.00% | -669.11% | -693.91% |
| 2022 | $39.02M | $-69.46M | 100.00% | -167.75% | -178.01% |
| 2023 | $18.14M | $-72.85M | 100.00% | -430.53% | -401.57% |
| 2024 | $6.17M | $-69.92M | 100.00% | -1,236.74% | -1,133.04% |
| 2025 | $14.08M | $-33.50M | 97.42% | -192.08% | -237.88% |